Clinical trials: Sweat Gland Diseases
Hidradenitis Suppurativa
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
- Trial name
- ABCESS2 (NCT05821478)
- Where
- 4 sites in France
- Volunteers
- 92 people
- Sponsor
- Institut Pasteur
Hidradenitis
A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a parallel, Phase 2b, 3-arm, double-blind, randomized, multicenter, multinational, placebo-controlled, dose-ranging study to evaluate the efficacy and the safety of different doses of duvakitug in adult participants with…
- Trial name
- AURALIGHT (NCT07812116)
- Testing
- Duvakitug
- Volunteers
- 156 people
- Sponsor
- Sanofi
Hidradenitis Suppurativa (HS)
Managed Access Programs for AIN457, Secukinumab
The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab
- Trial name
- NCT05583604
- Testing
- secukinumab
- Sponsor
- Novartis Pharmaceuticals
Chronic Infectious Disease, Chronic Skin Disease
Relationships Among Inflammation, Physical and Mental Health in Subjects With Chronic Inflammatory Physical Diseases.
The prevalence of common mental disorders is high in patients with chronic inflammatory physical diseases(e.g., autoimmune or infectious diseases).
- Conditions
- Chronic Infectious Disease, Chronic Skin Disease, Mental Disorders, Psoriasis
- Trial name
- InflaMent (NCT05125458)
- Where
- Italy
- Volunteers
- 93 people
- Sponsor
- University of Campania Luigi Vanvitelli
Hidradenitis Suppurativa (HS)
Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa
- Trial name
- NCT07244510
- Testing
- SCT650C
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Sinocelltech Ltd.
Hidradenitis Suppurativa
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- NCT05216224
- Testing
- ATI-450
- Where
- 20 sites in United States
- Volunteers
- 95 people
- Sponsor
- Aclaris Therapeutics, Inc.
Primary Axillary Hyperhidrosis
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis
The aim of the study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of escalating concentrations of GPB in subjects with axillary hyperhidrosis.
- Trial name
- NCT03037788
- Testing
- WO3979, WO3970, WO3992
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Hidradenitis Suppurativa
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD EXT (NCT04901195)
- Testing
- Bimekizumab
- Where
- 145 sites in United States, Australia and 17 more
- Volunteers
- 658 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa (HS)
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
- Trial name
- NCT07213973
- Testing
- Povorcitinib
- Where
- 30 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Acne, Acne Vulgaris
A Pilot Study to Explore the Role of Gut Flora in Acne
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Acne, Acne Vulgaris, Acne Keloidalis, Acne Keloid
- Trial name
- NCT04214483
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Hyperhydrosis, Depression
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)
The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, glycopyrrolate (approved to treat ulcers), which will be added to the antidepressant.
- Trial name
- AIDES-G (NCT01588717)
- Testing
- Glycopyrrolate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Amputation, Hyperhidrosis
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
This is a Prospective, Double Blinded, Placebo Controlled, Randomized, Cross-over trial using Qbrexza Cloths to treat hyperhidrosis of amputation sites.
- Trial name
- NCT04924036
- Testing
- glycopyrronium cloths
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Utah
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hidradenitis Suppurativa
Complement C5a Receptors in Hidradenitis Suppurativa
To study the role of C5a in Hidradenitis Suppurativa (HS). Complement C5a is a major chemotactic factor that stimulates neutrophil infiltration.
- Trial name
- NCT04251663
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Stanford University
Hidradenitis Suppurativa
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT03607487
- Testing
- INCB054707
- Where
- 13 sites in Canada, Denmark and 1 more
- Volunteers
- 35 people
- Sponsor
- Incyte Corporation
Hyperhidrosis
Laser Acupuncture Versus Tap Water Iontophoresis on Hyperhidrosis
the purpose of the present study is to assess the effect of laser acupoints on subjects with hyperhidrosis in comparison to tap water iontophoresis
- Trial name
- NCT04862546
- Testing
- Laser Acupoint, Tap water iontophoresis
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Hidradenitis Suppurativa
A Study of Bermekimab in Patients With Hidradenitis Suppurativa
Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
- Trial name
- NCT03512275
- Testing
- Bermekimab Monoclonal Antibody 400 mg
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Janssen Research & Development, LLC
Fabry Disease
An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
This study will evaluate the safety of multiple biweekly intravenous doses of Replagal over 26 weeks in 25 children with Fabry disease and the way in which that agent can improve the health of this patient population.
- Trial name
- NCT00071877
- Testing
- Replagal
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Cancer
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these…
- Trial name
- NCT00003938
- Testing
- liposomal amphotericin B
- Where
- 24 sites in Belgium, Czechia and 13 more
- Volunteers
- 115 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC